Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Authors:
- Kerstin PfisterKPKerstin Pfister
- Sophia HuesmannSHSophia Huesmann
- Angelina FinkAFAngelina Fink
- Thomas W. P. FriedlTFThomas W. P. Friedl
- Franziska MergelFMFranziska Mergel
- Henning P. SchäfflerHSHenning P. Schäffler
- Andreas HartkopfAHAndreas Hartkopf
- Stefan LukacSLStefan Lukac
- Kristina VeselinovicKVKristina Veselinovic
- Forca MehmetiFMForca Mehmeti
- Nathan CampbellNCNathan Campbell
- Christodoulos PipinikasCPChristodoulos Pipinikas
Open Access
- 1 September 2025
- journal article
- case report
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8498
Abstract
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a tumor-informed approach 12 months after the initial diagnosis and remained positive throughout adjuvant therapy with letrozole, while routine staging examinations showed no signs of relapse. Clinical relapse was ultimately identified nearly six years after the initial diagnosis, resulting in a lead time of four years and nine months. Current studies on ctDNA in the adjuvant setting have been conducted in high-risk cohorts and have shown a median molecular lead time of 8.9–12.4 months. Our study supports the need for large randomized clinical trials involving low-risk breast cancer patients to drive changes in clinical practice.Keywords
This publication has 17 references indexed in Scilit:
- Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysisESMO Open, 2024
- High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trialNature Medicine, 2023
- Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinomaBritish Journal of Cancer, 2022
- Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancerCell Death & Disease, 2020
- lncRNA TTN‐AS1 facilitates proliferation, invasion, and epithelial‐mesenchymal transition of breast cancer cells by regulating miR‐139‐5p/ZEB1 axisJournal of Cellular Biochemistry, 2020
- Assessment of Molecular Relapse Detection in Early-Stage Breast CancerJAMA Oncology, 2019
- EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesisOncogene, 2018
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Intensive Diagnostic Follow-up After Treatment of Primary Breast CancerJAMA, 1994
- Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer PatientsJAMA, 1994